This document provides information about pneumonia, including epidemiology, common causes, diagnosis, treatment, and prevention. It notes that pneumonia affects over 3 million people annually in the US, with higher rates in winter and among males and those over 65. Diagnosis involves clinical assessment of symptoms and signs, with chest x-ray and testing to confirm. Treatment depends on location of acquisition and risk factors, starting with broad-spectrum antibiotics and later targeting likely pathogens. Prevention focuses on vaccination, especially for influenza and pneumococcus, and reducing risk factors like smoking.
Pneumonia is an inflammation of the lung parenchyma caused by various microorganisms, including bacteria, mycobacteria, fungi, and viruses.
Pneumonitis is a more general term that describes the inflammatory process in the lung tissue that may predispose and Pneumonia is an inflammation of the lung parenchyma that is caused by a microbial agent.
place the patient at risk for microbial invasion.
Pneumonia is classified into four: community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), pneumonia in the immunocompromised host, and aspiration pneumonia.
Pneumonia - Community Acquired Pneumonia (CAP)Arshia Nozari
An overview to Community Acquired Pneumonia; It's Pathophysiology, Etiology, Epidemiology, Diagnosis and Treatment according to Harrison's Internal Medicine, 20th Edition (2018).
Pneumonia is an inflammatory condition of the lung affecting primarily the small air sacs known as alveoli. Typically symptoms include some combination of productive or dry cough, chest pain, fever, and trouble breathing. Severity is variable.
Pneumonia is usually caused by infection with viruses or bacteria and less commonly by other microorganisms, certain medications and conditions such as autoimmune diseases. Risk factors include cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, diabetes, heart failure, a history of smoking, a poor ability to cough such as following a stroke, and a weak immune system. Diagnosis is often based on the symptoms and physical examination. Chest X-ray, blood tests, and culture of the sputum may help confirm the diagnosis. The disease may be classified by where it was acquired with community, hospital, or health care associated pneumonia.
Vaccines to prevent certain types of pneumonia are available. Other methods of prevention include handwashing and not smoking. Treatment depends on the underlying cause. Pneumonia believed to be due to bacteria is treated with antibiotics. If the pneumonia is severe, the affected person is generally hospitalized. Oxygen therapy may be used if oxygen levels are low.
Pneumonia affects approximately 450 million people globally (7% of the population) and results in about four million deaths per year. Pneumonia was regarded by William Osler in the 19th century as "the captain of the men of death". With the introduction of antibiotics and vaccines in the 20th century, survival improved. Nevertheless, in developing countries, and among the very old, the very young, and the chronically ill, pneumonia remains a leading cause of death. Pneumonia often shortens suffering among those already close to death and has thus been called "the old man's friend"
Pneumonia is an inflammation of the lung parenchyma caused by various microorganisms, including bacteria, mycobacteria, fungi, and viruses.
Pneumonitis is a more general term that describes the inflammatory process in the lung tissue that may predispose and Pneumonia is an inflammation of the lung parenchyma that is caused by a microbial agent.
place the patient at risk for microbial invasion.
Pneumonia is classified into four: community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), pneumonia in the immunocompromised host, and aspiration pneumonia.
Pneumonia - Community Acquired Pneumonia (CAP)Arshia Nozari
An overview to Community Acquired Pneumonia; It's Pathophysiology, Etiology, Epidemiology, Diagnosis and Treatment according to Harrison's Internal Medicine, 20th Edition (2018).
Pneumonia is an inflammatory condition of the lung affecting primarily the small air sacs known as alveoli. Typically symptoms include some combination of productive or dry cough, chest pain, fever, and trouble breathing. Severity is variable.
Pneumonia is usually caused by infection with viruses or bacteria and less commonly by other microorganisms, certain medications and conditions such as autoimmune diseases. Risk factors include cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, diabetes, heart failure, a history of smoking, a poor ability to cough such as following a stroke, and a weak immune system. Diagnosis is often based on the symptoms and physical examination. Chest X-ray, blood tests, and culture of the sputum may help confirm the diagnosis. The disease may be classified by where it was acquired with community, hospital, or health care associated pneumonia.
Vaccines to prevent certain types of pneumonia are available. Other methods of prevention include handwashing and not smoking. Treatment depends on the underlying cause. Pneumonia believed to be due to bacteria is treated with antibiotics. If the pneumonia is severe, the affected person is generally hospitalized. Oxygen therapy may be used if oxygen levels are low.
Pneumonia affects approximately 450 million people globally (7% of the population) and results in about four million deaths per year. Pneumonia was regarded by William Osler in the 19th century as "the captain of the men of death". With the introduction of antibiotics and vaccines in the 20th century, survival improved. Nevertheless, in developing countries, and among the very old, the very young, and the chronically ill, pneumonia remains a leading cause of death. Pneumonia often shortens suffering among those already close to death and has thus been called "the old man's friend"
PneumoniaCheck by ARC Medical, The link between diagnosis and treatment of Pn...Steve Koontz
The Need:
Pneumonia is a leading cause of death in children worldwide. Over 2 million children die from pneumonia each year and one child dies every 20 seconds. The problem with current diagnosis methods is one of sampling. Mouth and nose samples have contaminating bacteria, which result in many false positives. Additionally, the samples are unable to identify the pathogen; hospital stays are lengthened increasing the chances that cases will become complicated. Since the pathogen cannot be identified, patients receive broad-spectrum antibiotics, which are often unnecessary and can cause antibiotic resistance. Other methods, such as a chest x-ray, can identify fluid in the lungs, but cannot identify the specific pathogen causing the pneumonia.
The Device:
PneumoniaCheck uses fluid mechanics to separate the upper airway particles from the lower airway particles. The separation means that only a lung specimen is captured on the filter at the end of the device. This filter can then be analyzed using traditional microbiology methods or mor sensitive molecular DNA analysis to identify the specific pathogen causing pneumonia, or other lower respiratory infections. The ability to identify the specific pathogen will allow for more targeted antibiotic treatment or none at all if viral, which should reduce antibiotic resistance and other complications. PneumoniaCheck is an easy-to-use, noninvasive, disposable solution for collecting respiratory specimens to help reduce one of the world’s largest health problems. PneumoniaCheck may be used on patients three feet and taller.
RespiDx: The Respimometer Diagnostic Aid for Childhood PneumoniaLeith Greenslade
Learn more about an innovative new tool that assesses respiration rate and temperature in small children to aid in the diagnosis of pneumonia in low resource settings where access to x-rays is severely limited. The recipient of grants from Grand Challenges Israel and USAID's Development Innovation Ventures, RespiDx is now testing the effectiveness of the Respimometer in the Democratic Republic of Congo.
Tuberculosis Treatment Symposia - The CRUDEM Foundation presented in Milot, Haiti at Hôpital Sacré Coeur.
CRUDEM’s Education Committee (a subcommittee of the Board of Directors) sponsors one-week medical symposia on specific medical topics, i.e. diabetes, infectious disease. The classes are held at Hôpital Sacré Coeur and doctors and nurses come from all over Haiti to attend.
Hepatitis C
Patología de origen viral; a cargo del Virus de Hepatitis C (VHC), este agente afecta al hígado dando asi las manifestaciones clínicas. Esta es una enfermedad de carácter crónico, lo que le hace diferente a las otras hepatitis virales y se le asocia directamente con la cirrosis hepática y CA.
Esta presentación tiene un fin educativo y de enseñanza espero les sea útil.
Pneumonia lecture,Describe the common pathogenesis and pathogens of pneumonia
Discuss diagnosis and initial management of community acquired pneumonia (CAP)
Understand features of the Pneumonia PORT Severity Index
Discuss the IDSA/ATS guidelines and recommendations for final antibiotic choice
Understand issues in basic management for pneumonia in children, nursing home patients, and immunocompromised patients.
respiratory inspections are common in elderly people and often times,that tickles into the lungs.More often than not they have comorbiidites,like Diabetes,hypertension etc.Hence,the treatment has to be different and some times the prognosis is guarded
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
6. Epidemiology
More than 3 million cases occur annually in US
Pneumonia is most relevant in winter months
Incidence of Pneumonia is greater in Males than in females
Total number of deaths due to pneumonia has been higher in
females since 1980s
Individuals 65 years and older : Pneumonia and Influenza were
6th leading death in 2005
Close to 90% of deaths due to pneumonia and influenza occur in
this age group
Adjusted death rates for females: 17.9 deaths per 100,000
population
23.9 deaths per 100,000 population for males
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17. CAP HAP/VAP
S. Pneumonia
M.Pneumonia
H. Influenza
C. Pneumonia
Legionella
RSV
P.
Aeruginosa
K.
Pneumonia
E.Coli
S.
Marcescens
19. Diagnosis
● CAP vs. HCAP
– Community Acquired Pneumonia
● Pneumonia in a patient without extensive healthcare contact.
20. Diagnosis
● CAP vs. HCAP
– Healthcare Associated Pneumonia
● Associated with a higher risk of multidrug resistant bacteria.
● Pneumonia in a patient with extensive healthcare contact
– IV Drug/Chemo therapy within last 30 days
– Attendance at hospital/hemodialysis clinic within last 30 days
– Hospitaliztion for >2 days within last 90 days
– Residence in long term care facility
21. Diagnosis
● Common Clinical Symptoms
– Cough
– Pleuritic Chest Pain
– Dyspnea
– GI Upset
● Common Clinical Signs
– Fever
– Tachychardia
– Crackles in lungs
– Sputum Production
– AMS
Even combined, Signs and
Symptoms have a
sensitivity of <50%
26. Treatment
● Empiric Treatment should be started on ALL
clinically suspected cases.
– Early diagnosis and treatment significantly reduced
Mortality and Length of Stay
● Antimicrobial choice based on:
– Most likely pathogens
– Clinical data
– Risk Factors for resistance
– Comorbidities
27. CAP Treatment
● Empiric Outpatient
– Previously healthy patient
1.Macrolides (A.C.E) OR
2.Doxycycline
– Comorbidities, DM, Alcoholism, Immunosuppression,
Prior ABx use
1.Fluoroquinolones (-floxacins, [Levaquin]) OR
2.Beta-lactam(Amoxicillin/Ceftriaxone) AND Macrolides
● Consider Antipseudomonal for COPD
28. CAP Treatment
● Empiric Inpatient
– Non-ICU
1.Respiratory Fluoroquinolones OR
2.Antipseudomonal Beta-Lactam AND Macrolide
– Ceftriaxone, Cefotaxime; A.C.E.
– ICU
● Antipseudomonal B-Lactam AND Azithromycin
● Antipseudomonal B-Lactam AND Fluoroquinolone
● Fluoroquinolone AND Azetreonam
– MRSA
● Add Vancomycin OR Linezolid
29. CAP Treatment
● Empiric Inpatient
– Discharge appropriate when:
● Stable from pneumonia
● Tolerates PO meds
● No active medical conditions
● Safe environment for discharge
– There is no need for overnight observations when
switching from IV to PO meds.
30. HAP/VAP Treatment
● Empiric Inpatient
– One of the following (Gram Positive coverage):
● Antipseudomonal Cephalosporin: Cefepime, etc.
● Antipseudomonal Cabepenem: Imipenem, etc.
● Pipercillin-Tazobactam
● Penicillin Allergies
– Mild: Simple Graded Challenge
– Severe: Azetreonam
31. HAP/VAP Treatment
● Empiric Inpatient
– PLUS One of the following (B-lactam resistant Gram
Negative coverage):
● Antipseudomonal Fluoroquinolone: Ciprofloxacin
● Aminoglycoside: Gentamycin
– PLUS One of the following (MRSA coverage):
● Linezolid
● Vancomycin
● Telavacin